Skip to content

Cyrus Rohani-Shukla

6 papers in the library · 59 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

On the meaning of ‘plasticity’ in neuroscience and mental health research and its relation to the action of psychedelic therapy

May 13, 2026 Robin Carhart-Harris, Richard J. Zeifman, Lorenzo Pasquini et al. preprint

First-line dictionary definitions of ‘plasticity’ describe it as the ability (of a thing) to be shaped or molded; we call this ‘plasticity proper’. In neuroscience, however, ‘neural plasticity’ or ‘neuroplasticity’ is defined as an induced change in brain function or structure. These two plasticities are not the same. Several (but not all) popular biomarkers of neuroplasticity index part of an...

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.

Comprehensive Psychiatry July 1, 2025 Luca Pellegrini, Naomi A Fineberg, Sorcha O'Connor et al. 17 citations

Obsessive-compulsive disorder (OCD) is a common and disabling condition. A large proportion of patients fail to respond to first-line treatment with serotonin reuptake inhibitors either selective serotonin reuptake inhibitors (SSRIs) or clomipramine. Preliminary evidence suggests psilocybin, a serotonin receptor agonist, might be efficacious. We conducted a pharmacological challenge study to...

Study Protocol for ‘PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity’

Cureus January 29, 2025 Sorcha O'Connor, Kate Godfrey, Sara Reed et al. 2 citations

This study's results are expected to offer critical insights into the neural mechanisms underlying the effects of psilocybin-assisted therapy in treating OCD, and whether these correlate with changes in the cognitive features of the condition. As a secondary aim, it will ascertain whether a low, tolerable dose is a feasible and efficacious clinical treatment, and will provide crucial data to...

Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences.

PLoS One 2025 Eirini K. Argyri, Jules Evans, David Luke et al. 27 citations

Psychedelic induced mystical experiences have been largely assumed to drive the therapeutic effects of these substances, which may in part be mediated by changes in metaphysical beliefs. However, there is growing evidence that psychedelic experiences can also trigger long lasting distress. Studies of persisting difficulties suggest a high prevalence of ontological challenges (related to the way...

Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.

Cureus 2025 Sorcha O'Connor, Kate Godfrey, Sara Reed et al. correction

Background: Obsessive-compulsive disorder (OCD) is a complex condition marked by persistent distressing thoughts and repetitive behaviours. Despite its prevalence, the mechanisms behind OCD remain elusive, and current treatments are limited. This protocol outlines an investigative study for individuals with OCD, exploring the potential of psilocybin to improve key components of cognition...

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.

Pharmacological Research September 1, 2024 Giorgia Caspani, Simon Ruffell, WaiFung Tsang et al. 13 citations

Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around their partial agonism at the serotonin 2 A receptor, leading to enhanced neuroplasticity and brain connectivity changes that underlie positive mindset shifts. However, these accounts fail to recognise that the gut microbiota, acting via the gut-brain...